$1.87
+0.53%Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Conservative with tight liquidity: Low debt is positive, but current ratio warrants attention. Consider whether the company is efficiently deploying its equity capital.
RNTX • NASDAQ
| Rein Therapeutics Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||||
CURRENT ASSETS | |||||||||||
3.2M | 12.9M | 17.3M | 5.2M | 3.6M | 7M | 5.3M | 10.6M | 11.9M | 20.7M | 3.8M | |
0.0 | 0.0 | 0.0 | 16M | 42.3M | 6.8M | 13M | 10.1M | 38.9M | 0.0 | 0.0 | |
3.2M | 12.9M | 17.3M | 21.2M | 45.9M | 13.8M | 18.3M | 20.7M | 50.8M | 20.7M | 3.8M | |
0.0 | 116K | 207K | 0.0 | 2.2M | 1.9M | 1.2M | 1.1M | 1M | 333K | 258K | |
1.1M | 676K | 746K | 631K | 25K | 593K | 25K | 25K | 88K | 25K | 0.0 | |
4.3M | 13.7M | 18.3M | 21.9M | 48.2M | 16.3M | 19.6M | 21.8M | 51.8M | 21.1M | 4M | |
NON-CURRENT ASSETS | |||||||||||
0.0 | 1K | 19K | 110K | 280K | 15K | 6.4M | 7.3M | 154K | 107K | 351K | |
6.3M | 0.0 | 6.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
13.5M | 48.5M | 79.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
19.8M | 48.5M | 85.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 7.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2K | 2K | 2.2M | 24K | 24K | 0.0 | 568K | 1.2M | 694K | 841K | 1.6M | |
19.8M | 55.6M | 87.7M | 134K | 304K | 15K | 6.9M | 8.5M | 848K | 948K | 1.9M | |
24.2M | 69.2M | 106M | 22M | 48.5M | 16.3M | 26.5M | 30.3M | 52.7M | 22M | 5.9M | |
LIABILITIES | |||||||||||
CURRENT LIABILITIES | |||||||||||
4M | 911K | 1.2M | 1.7M | 1.2M | 1.6M | 1.5M | 1.7M | 1.6M | 2M | 641K | |
4M | 911K | 1.2M | 1.7M | 1.2M | 1.6M | 1.5M | 1.7M | 1.6M | 2M | 641K | |
0.0 | 1.5M | 2.9M | 1.5M | 3.1M | 2M | 3.6M | 3.2M | 2.9M | 1M | 1.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 168K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 48K | 33K | 93K | 0.0 | 446K | 0.0 | 0.0 | 0.0 | 0.0 | |
2.2M | 3.4M | 206K | 181K | 60K | 243K | 352K | 423K | 351K | 1.1M | 176K | |
6.2M | 5.7M | 4.4M | 3.4M | 4.5M | 4M | 5.8M | 5.4M | 4.9M | 4.1M | 2.5M | |
NON-CURRENT LIABILITIES | |||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 219K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.1M | 8.8M | 3.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 277K | 91.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 129.8M | 97.7M | |
1.1M | 9.1M | 94.7M | 0.0 | 69K | 219K | 4.6M | 5.3M | 0.0 | 129.8M | 97.7M | |
0.0 | 0.0 | 48K | 33K | 162K | 0.0 | 5M | 5.3M | 0.0 | 0.0 | 0.0 | |
7.2M | 14.8M | 99.1M | 3.4M | 4.6M | 4.2M | 10.4M | 10.7M | 4.9M | 133.8M | 100.3M | |
SHAREHOLDERS' EQUITY | |||||||||||
45M | 45M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
113K | 108K | 91K | 91K | 91K | 44K | 28K | 15K | 15K | 0.0 | 0.0 | |
373.1M | 360.7M | 295.4M | 291.4M | 289.3M | 231.4M | 214.1M | 188.1M | 184.8M | 2.5M | 1.9M | |
-401.3M | -351.4M | -288.5M | -272.8M | -245.5M | -219.3M | -198.1M | -168.5M | -136.9M | -114.3M | -96.2M | |
-62K | -18K | -63K | -48K | -13K | -2K | 7K | -5K | -33K | 0.0 | 0.0 | |
16.9M | 54.4M | 6.9M | 18.6M | 43.9M | 12.2M | 16M | 19.6M | 47.8M | -111.8M | -94.3M | |
16.9M | 54.4M | 6.9M | 18.6M | 43.9M | 12.2M | 16M | 19.6M | 47.8M | -111.8M | -94.3M | |
SUMMARY | |||||||||||
24.2M | 69.2M | 106M | 22M | 48.5M | 16.3M | 26.5M | 30.3M | 52.7M | 22M | 5.9M | |
0.0 | 0.0 | 0.0 | 16M | 42.3M | 6.8M | 13M | 10.1M | 38.9M | 0.0 | 0.0 | |
0.0 | 0.0 | 48K | 33K | 162K | 387K | 5M | 5.3M | 0.0 | 0.0 | 0.0 | |
-3.2M | -12.9M | -17.3M | -5.2M | -3.4M | -6.7M | -279K | -5.3M | -11.9M | -20.7M | -3.8M | |
28,039,000 | 28,039,000 | 28,039,000 | 28,039,000 | 28,039,000 | 28,039,000 | 28,039,000 | 28,039,000 | 28,039,000 | 28,039,000 | 28,039,000 |
RNTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 15, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 24, 2025 | October 23, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 09, 2025 | October 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 22, 2025 | September 16, 2025 | 2025 |
Continue your RNTX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.